BPI-9016M

BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma[1][2].

Product Specifications

CAS Number

[1528546-94-2]

Product Name Alternative

Trimethoprim 3-N-oxide

UNSPSC

12352005

Target

C-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bpi-9016m.html

Purity

97.13

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CNC=C(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=C5C(NCC5)=NC=C4)C(F)=C3

Molecular Formula

C25H18F2N4O3

Molecular Weight

460.43

References & Citations

[1]Zhang P, et al. BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1. Theranostics. 2018 Nov 12;8 (21) :5890-5902.|[2]Hu X, et al. First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.J Hematol Oncol. 2020 Jan 16;13 (1) :6.